Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Inks US Distribution Deal for Chemotoxicity Assay, Other Tests

NEW YORK — UK-based molecular diagnostics firm Yourgene Health said on Monday that it has signed on Immuno-Biological Laboratories (IBL-America) as a nonexclusive US distributor of its Elucigene DPYD chemotoxicity assay and certain other reproductive health tests.

Under the terms of the deal, Spring Lake Park, Minnesota-based IBL-America will distribute in the US Elucigene DPYD, which identifies cancer patients with an enzyme deficiency that can result in serious side effects from 5-fluorouracil treatment, as well as Yourgene's PCR-based tests for cystic fibrosis, male factor infertility, and invasive aneuploidy.

Yourgene said the tests will initially be sold by IBL-America for research use only to research groups and CLIA labs for in-house validation prior to clinical use. Yourgene said that it may pursue FDA registration of the tests depending on customer demand.

Additional terms of the deal were not disclosed.

"The appointment of IBL-America is an important pillar within our plans to penetrate the largest diagnostics market in the world with our full portfolio across the whole genomic testing lifecycle," Yourgene CEO Lyn Rees said in a statement.

In August, Yourgene agreed to acquire Canadian sample prep technology firm Coastal Genomics for up to $13.5 million. 

The Scan

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.